vs

Side-by-side financial comparison of C4 Therapeutics, Inc. (CCCC) and Castellum, Inc. (CTM). Click either name above to swap in a different company.

Castellum, Inc. is the larger business by last-quarter revenue ($12.6M vs $11.0M, roughly 1.1× C4 Therapeutics, Inc.). Castellum, Inc. runs the higher net margin — -10.5% vs -186.0%, a 175.4% gap on every dollar of revenue. On growth, C4 Therapeutics, Inc. posted the faster year-over-year revenue change (112.8% vs 21.9%). Over the past eight quarters, C4 Therapeutics, Inc.'s revenue compounded faster (90.4% CAGR vs 5.3%).

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

Castellum, Inc. is a U.S.-based cybersecurity and information technology services provider. It caters to government defense agencies, public sector entities, and commercial enterprise clients, offering threat detection, data protection, cloud security, and managed IT solutions to help organizations mitigate cyber risks and safeguard critical digital infrastructure.

CCCC vs CTM — Head-to-Head

Bigger by revenue
CTM
CTM
1.1× larger
CTM
$12.6M
$11.0M
CCCC
Growing faster (revenue YoY)
CCCC
CCCC
+90.9% gap
CCCC
112.8%
21.9%
CTM
Higher net margin
CTM
CTM
175.4% more per $
CTM
-10.5%
-186.0%
CCCC
Faster 2-yr revenue CAGR
CCCC
CCCC
Annualised
CCCC
90.4%
5.3%
CTM

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CCCC
CCCC
CTM
CTM
Revenue
$11.0M
$12.6M
Net Profit
$-20.5M
$-1.3M
Gross Margin
33.9%
Operating Margin
-210.1%
-11.1%
Net Margin
-186.0%
-10.5%
Revenue YoY
112.8%
21.9%
Net Profit YoY
40.7%
51.8%
EPS (diluted)
$-0.09
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCCC
CCCC
CTM
CTM
Q4 25
$11.0M
$12.6M
Q3 25
$11.2M
$14.6M
Q2 25
$6.5M
$14.0M
Q1 25
$7.2M
$11.7M
Q4 24
$5.2M
$10.3M
Q3 24
$15.4M
$11.6M
Q2 24
$12.0M
$11.5M
Q1 24
$3.0M
$11.3M
Net Profit
CCCC
CCCC
CTM
CTM
Q4 25
$-20.5M
$-1.3M
Q3 25
$-32.2M
$415.4K
Q2 25
$-26.0M
$-322.1K
Q1 25
$-26.3M
$-1.2M
Q4 24
$-34.6M
$-2.7M
Q3 24
$-24.7M
$-1.3M
Q2 24
$-17.7M
$-1.8M
Q1 24
$-28.4M
$-4.1M
Gross Margin
CCCC
CCCC
CTM
CTM
Q4 25
33.9%
Q3 25
37.6%
Q2 25
36.1%
Q1 25
39.0%
Q4 24
40.0%
Q3 24
42.7%
Q2 24
40.6%
Q1 24
39.8%
Operating Margin
CCCC
CCCC
CTM
CTM
Q4 25
-210.1%
-11.1%
Q3 25
-306.4%
3.0%
Q2 25
-441.0%
-2.7%
Q1 25
-402.9%
-12.7%
Q4 24
-728.4%
-15.7%
Q3 24
-183.9%
-11.9%
Q2 24
-178.6%
-13.6%
Q1 24
-1060.2%
-23.6%
Net Margin
CCCC
CCCC
CTM
CTM
Q4 25
-186.0%
-10.5%
Q3 25
-286.4%
2.8%
Q2 25
-402.6%
-2.3%
Q1 25
-363.7%
-10.0%
Q4 24
-667.8%
-26.6%
Q3 24
-160.6%
-11.0%
Q2 24
-147.6%
-16.0%
Q1 24
-933.2%
-36.3%
EPS (diluted)
CCCC
CCCC
CTM
CTM
Q4 25
$-0.09
$-0.02
Q3 25
$-0.44
$0.00
Q2 25
$-0.37
$0.00
Q1 25
$-0.37
$-0.01
Q4 24
$-0.50
$-0.05
Q3 24
$-0.35
$-0.02
Q2 24
$-0.26
$-0.03
Q1 24
$-0.41
$-0.08

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCCC
CCCC
CTM
CTM
Cash + ST InvestmentsLiquidity on hand
$74.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$256.6M
$35.8M
Total Assets
$359.1M
$41.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCCC
CCCC
CTM
CTM
Q4 25
$74.6M
Q3 25
$58.8M
Q2 25
$78.2M
Q1 25
$51.3M
Q4 24
$55.5M
Q3 24
$59.6M
Q2 24
$73.1M
Q1 24
$89.7M
Total Debt
CCCC
CCCC
CTM
CTM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
$8.0M
Q3 24
$8.3M
Q2 24
$8.7M
Q1 24
$9.0M
Stockholders' Equity
CCCC
CCCC
CTM
CTM
Q4 25
$256.6M
$35.8M
Q3 25
$154.4M
$36.7M
Q2 25
$174.1M
$31.8M
Q1 25
$195.1M
$26.1M
Q4 24
$216.0M
$20.2M
Q3 24
$242.7M
$12.0M
Q2 24
$247.1M
$12.1M
Q1 24
$258.3M
$12.8M
Total Assets
CCCC
CCCC
CTM
CTM
Q4 25
$359.1M
$41.9M
Q3 25
$265.5M
$46.3M
Q2 25
$296.5M
$43.4M
Q1 25
$319.5M
$41.1M
Q4 24
$349.6M
$37.8M
Q3 24
$376.1M
$28.8M
Q2 24
$381.1M
$29.5M
Q1 24
$398.4M
$30.5M
Debt / Equity
CCCC
CCCC
CTM
CTM
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
0.40×
Q3 24
0.69×
Q2 24
0.72×
Q1 24
0.70×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCCC
CCCC
CTM
CTM
Operating Cash FlowLast quarter
$-22.1M
$-661.7K
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCCC
CCCC
CTM
CTM
Q4 25
$-22.1M
$-661.7K
Q3 25
$-31.2M
$1.0M
Q2 25
$-12.1M
$214.2K
Q1 25
$-33.3M
$-2.5M
Q4 24
$-17.9M
$-394.4K
Q3 24
$-24.1M
$742.2K
Q2 24
$-5.0M
$748.6K
Q1 24
$-18.1M
$23.7K
Free Cash Flow
CCCC
CCCC
CTM
CTM
Q4 25
Q3 25
$-31.6M
$957.0K
Q2 25
Q1 25
Q4 24
$-17.9M
Q3 24
$-24.1M
$738.9K
Q2 24
$-5.2M
Q1 24
FCF Margin
CCCC
CCCC
CTM
CTM
Q4 25
Q3 25
-281.5%
6.5%
Q2 25
Q1 25
Q4 24
-346.5%
Q3 24
-157.2%
6.4%
Q2 24
-43.1%
Q1 24
Capex Intensity
CCCC
CCCC
CTM
CTM
Q4 25
Q3 25
3.7%
0.3%
Q2 25
Q1 25
Q4 24
0.1%
0.0%
Q3 24
0.1%
0.0%
Q2 24
1.6%
0.0%
Q1 24
0.0%
0.0%
Cash Conversion
CCCC
CCCC
CTM
CTM
Q4 25
Q3 25
2.41×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons